RT @TheLancetOncol: #AACR18 2-years results of the Checkmate-141 phase 3 trial on nivo vs IC in pts w/ #H&N cancer See QoL data analysis @…
RT @TheLancetOncol: #AACR18 2-years results of the Checkmate-141 phase 3 trial on nivo vs IC in pts w/ #H&N cancer See QoL data analysis @…
RT @TheLancetOncol: #AACR18 2-years results of the Checkmate-141 phase 3 trial on nivo vs IC in pts w/ #H&N cancer See QoL data analysis @…
RT @TheLancetOncol: #AACR18 2-years results of the Checkmate-141 phase 3 trial on nivo vs IC in pts w/ #H&N cancer See QoL data analysis @…
RT @TheLancetOncol: #AACR18 2-years results of the Checkmate-141 phase 3 trial on nivo vs IC in pts w/ #H&N cancer See QoL data analysis @…
RT @Nuth_OHR: @Nuth_OHR team in @NewcastleHosps is running a number of studies looking at immunotherapy in different cancers. Results from…
RT @TheLancetOncol: #AACR18 2-years results of the Checkmate-141 phase 3 trial on nivo vs IC in pts w/ #H&N cancer See QoL data analysis @…
RT @Nuth_OHR: @Nuth_OHR team in @NewcastleHosps is running a number of studies looking at immunotherapy in different cancers. Results from…
RT @TheLancetOncol: #AACR18 2-years results of the Checkmate-141 phase 3 trial on nivo vs IC in pts w/ #H&N cancer See QoL data analysis @…
RT @TheLancetOncol: #AACR18 2-years results of the Checkmate-141 phase 3 trial on nivo vs IC in pts w/ #H&N cancer See QoL data analysis @…
@Nuth_OHR team in @NewcastleHosps is running a number of studies looking at immunotherapy in different cancers. Results from other studies are encouraging. Better care and improved outcomes for our patients https://t.co/Fch1abNXP6
RT @TheLancetOncol: #AACR18 2-years results of the Checkmate-141 phase 3 trial on nivo vs IC in pts w/ #H&N cancer See QoL data analysis @…
RT @TheLancetOncol: #AACR18 2-years results of the Checkmate-141 phase 3 trial on nivo vs IC in pts w/ #H&N cancer See QoL data analysis @…
RT @TheLancetOncol: #AACR18 2-years results of the Checkmate-141 phase 3 trial on nivo vs IC in pts w/ #H&N cancer See QoL data analysis @…
#AACR18 2-years results of the Checkmate-141 phase 3 trial on nivo vs IC in pts w/ #H&N cancer See QoL data analysis @TheLancetOncol https://t.co/txqfhSIQay https://t.co/TqjUHJblCS
RT @amyprawira: Quality of life must indeed remain front and centre #headandneckcancer #immunotherapy #cancerheroes https://t.co/QIDUOFFYtO
CT phase 3: Nivolumab vs. single-agent therapy in recurrent or metastatic squamous cell carcinoma of head and neck https://t.co/TiscFErC1C
"Nivolumab vs therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of head & neck" https://t.co/gpXu6zpiz4
RT @MetastasisRS: Study suggests Nivolumab as the new standard of care for metastatic squamous cell carcinoma of the head and neck: https:/…
Study suggests Nivolumab as the new standard of care for metastatic squamous cell carcinoma of the head and neck: https://t.co/k9hfECvoqn
RT @TheLancetOncol: #qualityoflife #QOL from CheckMate 141: nivolumab vs investigator's choice in metastatic #hncsm #headandneckcancer http…
So excited with new discoveries made every month! https://t.co/A1rXjXVd9V
RT @DrNabilSaba: First report of its kind on effect of PD-1 inhibitors vs chemo on PRO in HNCA patients; https://t.co/0sRdb4jEV8
RT @DrNabilSaba: First report of its kind on effect of PD-1 inhibitors vs chemo on PRO in HNCA patients; https://t.co/0sRdb4jEV8
RT @DrNabilSaba: First report of its kind on effect of PD-1 inhibitors vs chemo on PRO in HNCA patients; https://t.co/0sRdb4jEV8
First report of its kind on effect of PD-1 inhibitors vs chemo on PRO in HNCA patients; https://t.co/0sRdb4jEV8
RT @TheLancetOncol: #qualityoflife #QOL from CheckMate 141: nivolumab vs investigator's choice in metastatic #hncsm #headandneckcancer http…
RT @TheLancetOncol: #qualityoflife #QOL from CheckMate 141: nivolumab vs investigator's choice in metastatic #hncsm #headandneckcancer http…
RT @TheLancetOncol: #qualityoflife #QOL from CheckMate 141: nivolumab vs investigator's choice in metastatic #hncsm #headandneckcancer http…
RT @OncoHebdo: #Nivolumab: qualité de vie dans le #cancer de la tête et du cou épidermoïde (CheckMate 141) https://t.co/22brtosmpp
#Nivolumab: qualité de vie dans le #cancer de la tête et du cou épidermoïde (CheckMate 141) https://t.co/22brtosmpp
Quality of life must indeed remain front and centre #headandneckcancer #immunotherapy #cancerheroes https://t.co/QIDUOFFYtO
RT @TheLancetOncol: #qualityoflife #QOL from CheckMate 141: nivolumab vs investigator's choice in metastatic #hncsm #headandneckcancer http…
#qualityoflife #QOL from CheckMate 141: nivolumab vs investigator's choice in metastatic #hncsm #headandneckcancer https://t.co/cW8L4Sy0Xu
RT @ICR_London: #ICRpaper Nivolumab vs standard, single-agent therapy [in carcinoma] of the head and neck… via @TheLancetOncol https://t.c…
《短信》 【頭頸部がん:二次治療】「ニボルマブ」治療の選択によって生活の質も改善。CheckMate 141試験の結果。〔Lancet Oncol〕 https://t.co/jpYskGIHov
RT @ICR_London: #ICRpaper Nivolumab vs standard, single-agent therapy [in carcinoma] of the head and neck… via @TheLancetOncol https://t.c…
RT @ICR_London: #ICRpaper Nivolumab vs standard, single-agent therapy [in carcinoma] of the head and neck… via @TheLancetOncol https://t.c…
#ICRpaper Nivolumab vs standard, single-agent therapy [in carcinoma] of the head and neck… via @TheLancetOncol https://t.co/RcbJPAbByw